Articles
11 June 2009
Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009

Forodesine

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
177
Views
135
Downloads

Authors

Forodesine is a potent, selective, transition state inhibitor (i) of the enzyme purine nucleoside phosphorylase (PNP). It’s mechanisms of action is distinct from other purine nucleoside analogues in that forodesine does not act through interaction with nucleic acid. Selective PNPi leads to intracellular accumulation of dGTP in target lymphocytes and subsequent apoptosis. In vitro, Tcell lymphocytes are sensitive to forodesine. Based on these observations, a series of studies in subjects with cutaneous T-cell lymphoma were performed with single agent forodesine.

Altmetrics

Downloads

Citations

Supporting Agencies

How to Cite



Forodesine. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.541